PALOMA2, a double-blind, phase III trial of palbociclib plus letrozole vs placebo plus letrozole as a first-line treatment of postmenopausal patients with ER+/HER2- advanced breast cancer was confirmatory and should be reported soon. The gene discussed is ESR1; the disease is breast cancer.